Category: neuroendocrine cancer
Governors of Louisiana and Montana Join Worldwide NET Cancer Awareness Campaign
Governor Bobby Jindal of Louisiana and Governor Brian Schweitzer of Montana have become the 6th and 7th United States governors to pledge their support to the first Worldwide NET Cancer Awareness Day on November 10, 2010. Governor Schweitzer wrote,…
READ MORE
5th United States Governor Supports Global Neuroendocrine Cancer Awareness Campaign
Pat Quinn, Governor of Illinois, has joined governors from Connecticut, Missouri, Mississippi, and Nebraska in support of the 1st Worldwide Neuroendocrine Cancer Awareness Day on November 10, 2010. With increased awareness both in the healthcare…
READ MORE
Connecticut Governor Issues Proclamation for Worldwide NET Cancer Awareness Day
M. Jodi Rell, Governor of Connecticut, has named November 10 as Worldwide NET Cancer Awareness Day. She is the fourth United States Governor to participate in the global campaign to raise awareness about carcinoid and neuroendocrine cancers and the …
READ MORE
Governor of Missouri Proclaims November 10, 2010 Neuroendocrine Cancer Awareness Day
In recognition of the first Worldwide NET Cancer Awareness Day, Jeremiah W. (Jay) Nixon, Governor of Missouri, has declared November 10, 2010 to be Neuroendocrine Cancer Awareness Day. In his proclamation, Governor Nixon talked about the importance…
READ MORE
Novartis Oncology Announces Winner of 2010 Warner Advocacy Award
Maryann Wahmann of the Carcinoid Cancer Awareness Network (CCAN) has been chosen as winner of the 2010 Warner Advocacy Award, established last year by Novartis Oncology to commemorate the life and work of the late Monica Warner of the Carcinoid Cancer…
READ MORE
2012 National Carcinoid & NETs Conference: Save the Date
Dr. Eugene A. Woltering, the Carcinoid Cancer Awareness Network (CCAN), and the New Orleans Neuroendocrine Tumor Specialist team at Ochsner Medical Center – Kenner in Louisiana have announced the dates for the 2012 National Carcinoid/NETs Conference…
READ MORE
Lexicon Pharmaceuticals, Inc. Clinical Trial Recruiting Carcinoid Syndrome Patients
Patients with carcinoid syndrome, whose symptoms are not managed by octreotide therapy, are being recruited for a Phase 2 clinical trial of Lexicon Pharmaceuticals’ LX1606 (a.k.a. LX1032). The trial has been given Fast Track status in the U.S. and …
READ MORE
FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)
For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…
READ MORE
10 More iPhone Apps for Patients and Physicians
If you are a carcinoid or neuroendocrine cancer iPhone user, a healthcare provider who treats carcinoid/NETs patients, or a medical student, here are 10 more iPhone apps that will give you information about everything from new drug warnings to places…
READ MORE
